The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
SITC 2021 | Advances in personalized medicine in NSLC
Afaf Abed, MBBS, FRACP, Fiona Stanley Hospital, Murdoch, Australia, describes progress in the development of personalized therapies for patients with non-small-cell lung cancer (NSCLC). With the exception of stratifying patients based on transthoracic needle biopsies (TNB) and certain biomarkers including PD-L1, the personalization of treatments remains limited for patients with NSCLC. Gene sequencing of cancers with technologies such as next-generation sequencing will identify novel mutations and biomarkers to better identify patients who will benefit from immunotherapy. This interview took place during the 36th Society for Immunotherapy of Cancer (SITC) Annual Meeting in Washington, D.C.
